COVID-19患者体外膜氧合支持:ELSO登记处国际队列研究
BACKGROUND: Multiple major health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for COVID-19-related acute hypoxaemic respiratory failure.…
核心结论
- COVID-19接受ECMO患者90天估计死亡率和最终死亡或出院者死亡率均低于40%。
- 来自全球213家医院的数据提供了COVID-19背景下ECMO死亡率的可推广估计。
研究设计与样本
- 国际多中心队列研究,使用ELSO登记处数据。
- 纳入2020年1月16日至5月1日在36国213家医院启动ECMO的≥16岁确诊COVID-19患者1035例。
- 主要结局为ECMO启动后90天院内死亡,采用时间-事件分析和多变量Cox模型。
主要发现
- 1035例中,67例(6%)仍住院,311例(30%)出院回家或急性康复中心,101例(10%)转长期急性护理中心或未指明地点,176例(17%)转至其他医院,380例(37%)死亡。
- 最终死亡或出院患者中死亡率为39%(380/968)。
临床怎么用
- 对于COVID-19相关急性低氧性呼吸衰竭,ECMO支持后90天死亡率低于40%,可为临床决策提供参考。
- 使用循环支持ECMO时需警惕更高的死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple major health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for COVID-19-related acute hypoxaemic respiratory failure. However, initial reports of ECMO use in patients with COVID-19 described very high mortality and there have been no large, international cohort studies of ECMO for COVID-19 reported to date. METHODS: We used data from the Extracorporeal Life Support Organization (ELSO) Registry to characterise the epidemiology, hospital course, and outcomes of patients aged 16 years or older with confirmed COVID-19 who had ECMO support initiated between Jan 16 and May 1, 2020, at 213 hospitals in 36 countries. The primary outcome was in-hospital death in a time-to-event analysis assessed at 90 days after ECMO initiation. We applied a multivariable Cox model to examine whether patient and hospital factors were associated with in-hospital mortality. FINDINGS: Data for 1035 patients with COVID-19 who received ECMO support were included in this study. Of these, 67 (6%) remained hospitalised, 311 (30%) were discharged home or to an acute rehabilitation centre, 101 (10%) were discharged to a long-term acute care centre or unspecified location, 176 (17%) were discharged to another hospital, and 380 (37%) died. The estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 37·4% (95% CI 34·4-40·4). Mortality was 39% (380 of 968) in patients with a final disposition of death or hospital discharge. The use of ECMO for circulatory support was independently associated with higher in-hospital mortality (hazard ratio 1·89, 95% CI 1·20-2·97). In the subset of patients with COVID-19 receiving respiratory (venovenous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 38·0% (95% CI 34·6-41·5). INTERPRETATION: In patients with COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or discharge were less than 40%. These data from 213 hospitals worldwide provide a generalisable estimate of ECMO mortality in the setting of COVID-19. FUNDING: None.
引用
- Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020. PMID: 32987008. doi:10.1016/S0140-6736(20)32008-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。